Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07735104 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The First in Human Study of QLS2319 in Healthy Subjects and Cancer Cachexia

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Primary endpoints: details revised at 1 of 2 entries · Study sites: 1 to 2 · Start date changed from estimate of Sep 1, 2026 to Sep 16, 2026 · 2 more Show 5 more changesShow less
    • Primary endpoints: details revised at 1 of 2 entries
    • Study sites: 1 to 2
    • Start date changed from estimate of Sep 1, 2026 to Sep 16, 2026
    • Eligibility criteria expanded, about 16 words
    • Study title shortened, about 5 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Study To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of QLS2319 in Healthy Subjects and Cancer Cachexia
Trial Details
NCT Number NCT07735104
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Cancer Cachexia, Cancer Cachexia Syndrome
Enrollment 88 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov